Venous Thromboembolism Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Venous Thromboembolism Market Report Overview

Venous thromboembolism market size across the 7MM was valued at $3.57 billion in 2022 and will achieve a CAGR of more than 2% during 2022-2032. The market growth can be attributed to the large size of the VTE patient population in the US as well as the higher overall price of drugs as compared to the 5EU and Japan.

Venous Thromboembolism Market Outlook, 2022-2032 ($ Billion)

Venous Thromboembolism Market Outlook, 2022-2032 ($ Billion)

Buy Full Report to Get More Insights into the Venous Thromboembolism Market Forecast

Download a Free Report Sample

The venous thromboembolism market research report provides a forecast model for the Venous Thromboembolism (VTE) market through 2032 and an overview of VTE, including epidemiology, symptoms, diagnosis, and disease management.

Market Size (2022) $3.57 billion
CAGR (2022 – 2032) >2%
Forecast Period 2022-2032
Key Countries ·       The US

·       France

·       Germany

·       Italy

·       Spain

Leading Players ·       Boehringer Ingelheim

·       Bayer/Janssen

·       BMS/Pfizer

·       Daiichi-Sankyo

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Venous Thromboembolism Market Insights

Generic erosion as NOAC patents expire is hampering the market growth. However, NOAC generics will capture a larger percentage of VTE patients as the drugs become more affordable thereby will propel the venous thromboembolism market growth during the forecast period.

Venous Thromboembolism Market - Treatment Insights

  • Anthos Therapeutics is conducting two trials including ASTER and MAGNOLIA. The former compares abelacimab to Eliquis (apixaban) in the treatment of cancer-associated VTE, while the latter examines abelacimab against dalteparin in the treatment of gastrointestinal/genitourinary cancer and associated VTE.
  • NOACs provide several significant benefits over previously popular anticoagulants such as warfarin and Lovenox in terms of improved safety and a lack of need for routine monitoring. They already command a significant share of the global VTE treatment market.

Buy Full Report to Get More Insights into the Venous Thromboembolism Treatment Insights

Download a Free Report Sample

Venous Thromboembolism Market Segmentation by Countries

Some of the key countries in the VTE market are the US, France, Germany, Italy, Spain, the UK, and Japan. The US had the highest share of the market in 2022.

Venous Thromboembolism Market Analysis by Countries, 2022 (%)

Venous Thromboembolism Market Analysis by Countries, 2022 (%)

Buy Full Report to Get More Insights into the Venous Thromboembolism Market Countries

Download a Free Report Sample

Venous Thromboembolism Market - Competitive Landscape

A few of the leading players in the venous thromboembolism market are:

  • Boehringer Ingelheim
  • Bayer/Janssen
  • BMS/Pfizer
  • Daiichi-Sankyo

Until 2010, the VTE space was dominated by anticoagulants such as warfarin, VKAs, fondaparinux, and heparins (LMWH and UF) developed by a variety of pharma companies. With no clear market leader and the entrance of NOACs, Boehringer Ingelheim, Janssen/Bayer, BMS/Pfizer, and Daiichi-Sankyo have been able to become strong players with their drugs Pradaxa, Xarelto, Eliquis, and Savaysa/Lixiana, respectively.

Venous Thromboembolism Market Analysis

Venous Thromboembolism Market Analysis

Buy Full Report to Get More Insights into the Venous Thromboembolism Market Companies

Download a Free Report Sample

Segments Covered in the Report

Venous Thromboembolism Country Outlook (Value, $ Billion, 2022-2032)

  • The US
  • France
  • Germany
  • Italy
  • Spain

Scope

This report provides:

  • Annualized VTE therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
  • Strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the VTE market.
  • Comprehensive data assessing emerging trends and mechanisms of action under development for VTE treatment and prophylaxis. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the 7MM VTE therapeutics market, insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

Report deliverables include:

  • Word report and an Excel-based forecast model
  • Forecast includes the 7 major markets (7MM)
  • Forecast covers the period 2022-2032.

The minimal growth is due to the generic erosion that will occur as patents for novel oral anticoagulants (NOACs) expire throughout the forecast period as well as only one late-stage pipeline therapy that will only capture a small share of the market due to its high cost, subcutaneous method of administration, and lack of strong clinical trial data.

Reasons to Buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 7MM obesity therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM VTE therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Anthos Therapeutics
Bayer
Boehringer Ingelheim
Bristol Myers Squibb
Daiichi-Sankyo
Janssen
Pfizer

Table of Contents

About GlobalData 2

1 Venous Thromboembolism: Executive Summary 9

1.1 The VTE market will experience minimal growth between 2022 and 2032 10

1.2 Companies are focusing clinical trial development on factor XI inhibitors 11

1.3 Optimal treatment strategies for patients with cancer or renal impairment are needed 12

1.4 Abelacimab to contribute moderately to sales during the forecast period 13

1.5 What do physicians think? 14

2 Introduction 16

2.1 Catalyst 16

2.2 Related reports 16

2.3 Upcoming reports 16

3 Disease Overview 17

3.1 Etiology and pathophysiology 17

3.1.1 Etiology 18

3.1.2 Pathophysiology 19

4 Epidemiology 21

4.1 Disease background 21

4.2 Risk factors and comorbidities 22

4.3 Global and historical trends 24

4.4 7MM forecast methodology 25

4.4.1 Sources 25

4.4.2 Forecast assumptions and methods 31

4.4.3 Diagnosed incident cases of PE, DVT, and VTE 31

4.4.4 Diagnosed incident cases of DVT by anatomical region 34

4.4.5 Diagnosed incident cases of VTE by provoking risk factor 35

4.4.6 Diagnosed incident cases of VTE with cancer as a comorbidity 36

4.4.7 Diagnosed incident cases of VTE with chronic kidney disease (CKD) as a comorbidity 37

4.4.8 Diagnosed VTE attacks 38

4.4.9 Number of one- and 10-year first time recurrent cases of VTE 39

4.4.10 Number of hospital discharges meeting medically ill criteria 40

4.4.11 Number of hospital discharges meeting medically ill criteria at risk for VTE 42

4.4.12 Number of total hip and knee replacements 42

4.5 Epidemiological forecast for venous thromboembolism (VTE) (2022–32) 44

4.5.1 Diagnosed incident cases of PE 44

4.5.2 Diagnosed incident cases of DVT 45

4.5.3 Diagnosed incident cases of VTE 46

4.5.4 Age-specific diagnosed incident cases of VTE 47

4.5.5 Sex-specific diagnosed incident cases of VTE 48

4.5.6 Diagnosed incident cases of DVT by anatomical region 49

4.5.7 Number of diagnosed incident cases of VTE by provoking risk factor 50

4.5.8 One- and 10-year first time diagnosed recurrent cases of VTE 51

4.5.9 Diagnosed incident cases of VTE with cancer as a comorbidity 52

4.5.10 Diagnosed incident cases of VTE with CKD as a comorbidity 53

4.5.11 Number of diagnosed VTE attacks 54

4.5.12 Number of hospital discharges meeting medically ill criteria at risk for VTE 55

4.5.13 Total number of knee replacements 56

4.5.14 Total number of hip replacements 57

4.6 Discussion 58

4.6.1 Epidemiological forecast insight 58

4.6.2 COVID-19 impact 58

4.6.3 Limitations of the analysis 59

4.6.4 Strengths of the analysis 60

5 Disease Management 61

5.1 Diagnosis and treatment overview 61

5.2 Key opinion leader insights on disease management 67

6 Competitive Assessment 69

6.1 Overview 69

7 Unmet Needs and Opportunity Assessment 70

7.1 Overview 70

7.2 Mitigating bleeding risk 71

7.3 Optimal treatment for cancer patients 72

7.4 Optimal treatment for patients with renal impairment and renal failure 74

7.5 Complications associated with parenteral therapies 75

7.6 Improved education among physicians and patients 76

8 R&D Strategies 78

8.1 Overview 78

8.1.1 Development of drugs with novel targets: factor XI inhibitors 78

8.2 Clinical trials design 79

8.2.1 Improvements in quantifying and reporting bleeding risk 80

8.2.2 Need for trial design that accounts for both short and long-term clinical outcomes 81

8.2.3 Comparators for clinical trials based in Japan 81

9 Pipeline Assessment 83

9.1 Overview 83

9.2 Promising drugs in clinical development 84

10 Pipeline Valuation Analysis 88

10.1 Overview 88

10.2 Competitive assessment 88

11 Current and Future Players 91

11.1 Overview 91

11.2 Deal-making trends 92

12 Market Outlook 94

12.1 Global markets 94

12.1.1 Forecast 94

12.1.2 Drivers and barriers – global issues 95

12.2 US 96

12.2.1 Forecast 96

12.2.2 Key events 98

12.2.3 Drivers and barriers 99

12.3 5EU 99

12.3.1 Forecast 99

12.3.2 Key events 101

12.3.3 Drivers and barriers 102

12.4 Japan 102

12.4.1 Forecast 102

12.4.2 Key events 104

12.4.3 Drivers and barriers 105

13 Appendix 106

13.1 Bibliography 106

13.2 Abbreviations 112

13.3 Methodology 113

13.3.1 Forecasting methodology 113

13.4 Primary research – key opinion leaders interviewed for this report 114

13.4.1 Key opinion leaders 114

13.4.2 Payers 117

13.5 Primary research – prescriber survey 118

13.6 About the Authors 119

13.6.1 Senior Analyst 119

13.6.2 Therapy Area Director 119

13.6.3 Epidemiologist 119

13.6.4 Reviewers 119

13.6.5 Vice President of Disease Analysis and Intelligence 121

13.6.6 Global Head and EVP of Healthcare Operations and Strategy 121

Contact Us 122

Table

Table 1: VTE: key metrics in the 7MM 9

Table 2: Risk factors and comorbidities for VTE 23

Table 3: Treatment guidelines for VTE 66

Table 4: VTE market – global drivers and barriers, 2022–32 95

Table 5: Key events impacting sales for VTE in the US, 2022–32 98

Table 6: VTE market – drivers and barriers in the US, 2022–32 99

Table 7: Key events impacting sales for VTE in the 5EU, 2022–32 101

Table 8: VTE market – drivers and barriers in the 5EU, 2022–32 102

Table 9: Key events impacting sales for VTE in Japan, 2022–32 104

Table 10: VTE market – drivers and barriers in Japan, 2022–32 105

Table 11: High-prescribing physicians (non-KOLs) surveyed, by country 118

Figures

Figure 1: Global sales forecast by country for VTE in 2022 and 2032 11

Figure 2: Analysis of the company portfolio gap in venous thromboembolism during the forecast period 12

Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of venous thromboembolism during the forecast period 13

Figure 4: 7MM, diagnosed incidence of PE, DVT, and VTE, cases per 100,000 population, both sexes, all ages, 2022 25

Figure 5: 7MM, sources used to forecast the diagnosed incident cases of PE, DVT, and VTE 26

Figure 6: 7MM, sources used to forecast the diagnosed incident cases of DVT by anatomical region 27

Figure 7: 7MM, sources used to forecast the diagnosed incident cases of VTE by provoking risk factor 27

Figure 8: 7MM, sources used to forecast the diagnosed incident cases of VTE with cancer as a comorbidity 28

Figure 9: 7MM, sources used to forecast the diagnosed incident cases of VTE with CKD as a comorbidityu 28

Figure 10: 7MM, sources used to forecast the diagnosed VTE attacks 29

Figure 11: 7MM, sources used to forecast VTE recurrence after one and 10 years 29

Figure 12: 7MM, sources used to forecast the number of hospital discharges that meet medically ill criteria and are at risk of VTE 30

Figure 13: 7MM, sources used and not used to forecast the primary total knee replacements and revisions, and hip replacements. 30

Figure 14: 7MM, diagnosed incident cases of PE, N, both sexes, all ages, 2022 44

Figure 15: 7MM, diagnosed incident cases of DVT, N, both sexes, all ages, 2022 45

Figure 16: 7MM, diagnosed incident cases of VTE, N, both sexes, all ages, 2022 46

Figure 17: 7MM, diagnosed incident cases of VTE by age, N, both sexes, all ages, 2022 47

Figure 18: 7MM, diagnosed incident cases of VTE by sex, N, both sexes, all ages, 2022 48

Figure 19: 7MM, diagnosed incident cases of DVT by anatomical region, N, all ages, 2022 49

Figure 20: 7MM, diagnosed incident cases of VTE by provoking risk factor, N, both sexes, all ages, 2022 50

Figure 21: 7MM, first-time recurrent cases of VTE, N, both sexes, all ages, 2022 51

Figure 22: 7MM, diagnosed incident cases of VTE with cancer as a comorbidity, N, both sexes, all ages, 2022 52

Figure 23: 7MM, diagnosed incident cases of VTE with CKD as a comorbidity, N, both sexes, 2022 and 2032 53

Figure 24: 7MM, diagnosed VTE attacks, N, both sexes, all ages, 2022 and 2032 54

Figure 25: 7MM, number of medically ill hospital discharges at risk for VTE, N, both sexes, ≥40 years, 2022 55

Figure 26: 7MM, total number of knee replacements, N, both sexes, ≥15 years, 2022 and 2032 56

Figure 27: 7MM, total number of hip replacements, N, both sexes, ≥15 years, 2022 and 2032 57

Figure 28: Treatment algotrithm for VTE 62

Figure 29: Unmet needs and opportunities in VTE 70

Figure 30: Overview of the development pipeline in VTE 84

Figure 31: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for VTE in the 7MM during the forecast period 86

Figure 32: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of VTE during the forecast period 86

Figure 33: Competitive assessment of the marketed and pipeline drugs benchmarked against the SOC: NOACs 90

Figure 34: Analysis of the company portfolio gap in VTE during the forecast period 92

Figure 35: Deal-making trends, number of deals, 2018–22 93

Figure 36: Deal-making trends, value of deals, 2018–22 93

Figure 37: 7MM sales forecast by country for VTE in 2022 and 2032 95

Figure 38: Sales forecast by class for VTE treatment in the US in 2022 and 2032 97

Figure 39: Sales forecast by class for VTE primary prophylaxis in the US in 2022 and 2032 98

Figure 40: Sales forecast by country for VTE treatment and primary prophylaxis in the 5EU in 2022 and 2032 100

Figure 41: Sales forecast by class for VTE treatment and primary prophylaxis in the 5EU in 2022 and 2032 101

Figure 42: Sales forecast by class for VTE treatment in Japan in 2022 and 2032 103

Figure 43: Sales forecast by class for VTE primary prophylaxis in Japan in 2022 and 2032 104

Frequently asked questions

Venous Thromboembolism Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Venous Thromboembolism Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
5-Hydroxytryptamine Receptor 2A - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
Mu Type Opioid Receptor - Drugs In Development, 2024
$3,500 | June 2024
Pharmaceuticals
New
GTPase KRas - Drugs In Development, 2024
$3,500 | June 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Venous Thromboembolism Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032 in real time.

  • Access a live Venous Thromboembolism Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2032 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.